Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atogepant Clear all
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
138
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 2, 2026, 10:00 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293
View directory record Official record
Conditions
Menstrual Migraine (MM)
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320
View directory record Official record
Conditions
Episodic Migraine
Interventions
Standard of Care (SOC) Migraine Preventive Medication, Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
112
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 2, 2026, 10:00 PM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

NCT06972056
View directory record Official record
Conditions
Migraine
Interventions
Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
1,335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Recruiting No phase listed Observational

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750
View directory record Official record
Conditions
Migraine, Episodic Migraine, Chronic Migraine, Headache
Interventions
CGRP antibody or gepant
Drug
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

NCT05264129
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 1 Interventional

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

NCT05892757
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Springfield, Missouri • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 2, 2026, 10:00 PM EDT
Active, not recruiting No phase listed Observational

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Hoover, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Atogepant 60 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 2, 2026, 10:00 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
35
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 2, 2026, 10:00 PM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
31
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

NCT03855137
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant 30 mg, Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 2, 2026, 10:00 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo-Matching Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 1 Interventional

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

NCT04818515
View directory record Official record
Conditions
Migraine
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Orlando, Florida • Springfield, Missouri • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 2, 2026, 10:00 PM EDT
Completed No phase listed Observational

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

NCT05653986
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 2, 2026, 10:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 2, 2026, 10:00 PM EDT
Recruiting No phase listed Observational

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

NCT05158894
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 2, 2026, 10:00 PM EDT